Comparative Pharmacology
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIAVIL 2 10 versus TRIAVIL 4 50.
TRIAVIL 2-10 vs TRIAVIL 4-50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRIAVIL 2-10 is a fixed-dose combination of amitriptyline (a tricyclic antidepressant) and perphenazine (a phenothiazine antipsychotic). Amitriptyline inhibits reuptake of serotonin and norepinephrine, enhancing neurotransmission. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic activity in the mesolimbic pathway.
Amitriptyline is a tricyclic antidepressant that inhibits reuptake of serotonin and norepinephrine. Perphenazine is a typical antipsychotic that blocks dopamine D2 receptors.
1 tablet (perphenazine 2 mg / amitriptyline 10 mg) orally 3 to 4 times daily. Maximum: perphenazine 64 mg/day, amitriptyline 300 mg/day.
One tablet (4 mg perphenazine / 50 mg amitriptyline) orally three times daily to four times daily. Maximum: 8 tablets per day.
None Documented
None Documented
Amitriptyline: 10-50 hours (mean 20h). Perphenazine: 8-21 hours (mean 12h). Clinically, steady state reached in 3-10 days; dose adjustments should consider accumulation.
Amitriptyline: 15-40 hours (mean 20-30 hours); perphenazine: 9-12 hours; clinical context: steady-state achieved within 5-7 days, dosing adjustments needed in hepatic impairment.
Renal excretion accounts for approximately 50-60% of total clearance for amitriptyline (metabolites) and 20-30% for perphenazine (metabolites). Biliary/fecal elimination of metabolites contributes 10-20%.
Renal: 50-60% as metabolites (amitriptyline and perphenazine), <5% unchanged; fecal: 20-30% (primarily perphenazine metabolites); biliary: minor route for perphenazine.
Category C
Category C
Antidepressant-Antipsychotic Combination
Antidepressant-Antipsychotic Combination